How much did Shanghai Junshi Biosciences Co achieve in EBIT for the current year?
In the current year, Shanghai Junshi Biosciences Co has achieved an EBIT of -1.13 B CNY.
Shanghai Junshi Biosciences Co EBIT 2025
Shanghai Junshi Biosciences Co EBIT
-1.13 B CNY
Ticker
688180.SS
ISIN
CNE1000041Z1
In 2025, Shanghai Junshi Biosciences Co's EBIT was -1.13 B CNY, a -7.28% increase from the -1.22 B CNY EBIT recorded in the previous year.
The Shanghai Junshi Biosciences Co EBIT history
| YEAR | EBIT (undefined CNY) |
|---|---|
| 2029e | - |
| 2028e | 1.24 |
| 2027e | 0.85 |
| 2026e | -1 |
| 2025e | -1.13 |
| 2024e | -1.22 |
| 2023 | -2.48 |
| 2022 | -2.72 |
| 2021 | -0.59 |
| 2020 | -1.68 |
| 2019 | -0.77 |
| 2018 | -0.69 |
| 2017 | -0.3 |
Shanghai Junshi Biosciences Co Revenue, EBIT, Net Income CNE1000041Z1 ·
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Shanghai Junshi Biosciences Co, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Shanghai Junshi Biosciences Co from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Shanghai Junshi Biosciences Co’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Shanghai Junshi Biosciences Co. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Shanghai Junshi Biosciences Co’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Shanghai Junshi Biosciences Co’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Shanghai Junshi Biosciences Co’s growth potential.
Shanghai Junshi Biosciences Co Revenue, EBIT and net profit per share
| Date | Shanghai Junshi Biosciences Co Revenue | Shanghai Junshi Biosciences Co EBIT | Shanghai Junshi Biosciences Co Net Income |
|---|---|---|---|
| 2029e | 5.76 B undefined | 0 undefined | 0 undefined |
| 2028e | 5.25 B undefined | 1.24 B undefined | 0 undefined |
| 2027e | 4.77 B undefined | 851.49 M undefined | 0 undefined |
| 2026e | 3.73 B undefined | -995.86 M undefined | -263.82 M undefined |
| 2025e | 2.73 B undefined | -1.13 B undefined | -667.02 M undefined |
| 2024e | 1.79 B undefined | -1.22 B undefined | -1.44 B undefined |
| 2023 | 1.5 B undefined | -2.48 B undefined | -2.28 B undefined |
| 2022 | 1.45 B undefined | -2.72 B undefined | -2.39 B undefined |
| 2021 | 4.02 B undefined | -594.04 M undefined | -720.91 M undefined |
| 2020 | 1.59 B undefined | -1.68 B undefined | -1.67 B undefined |
| 2019 | 775.1 M undefined | -774.2 M undefined | -747.4 M undefined |
| 2018 | 2.9 M undefined | -688.1 M undefined | -722.9 M undefined |
| 2017 | 54.5 M undefined | -298.7 M undefined | -317.3 M undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2017 | 54.5 M CNY | -298.7 M CNY | -317.3 M CNY |
| 2018 | 2.9 M CNY | -688.1 M CNY | -722.9 M CNY |
| 2019 | 775.1 M CNY | -774.2 M CNY | -747.4 M CNY |
| 2020 | 1.59 B CNY | -1.68 B CNY | -1.67 B CNY |
| 2021 | 4.02 B CNY | -594.04 M CNY | -720.91 M CNY |
| 2022 | 1.45 B CNY | -2.72 B CNY | -2.39 B CNY |
| 2023 | 1.5 B CNY | -2.48 B CNY | -2.28 B CNY |
| 2024e | 1.79 B CNY | -1.22 B CNY | -1.44 B CNY |
| 2025e | 2.73 B CNY | -1.13 B CNY | -667.02 M CNY |
| 2026e | 3.73 B CNY | -995.86 M CNY | -263.82 M CNY |
| 2027e | 4.77 B CNY | 851.49 M CNY | 0 CNY |
| 2028e | 5.25 B CNY | 1.24 B CNY | 0 CNY |
| 2029e | 5.76 B CNY | 0 CNY | 0 CNY |
Shanghai Junshi Biosciences Co stock margins CNE1000041Z1 ·
The Shanghai Junshi Biosciences Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Shanghai Junshi Biosciences Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Shanghai Junshi Biosciences Co.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Shanghai Junshi Biosciences Co's sales revenue. A higher gross margin percentage indicates that the Shanghai Junshi Biosciences Co retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Shanghai Junshi Biosciences Co's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Shanghai Junshi Biosciences Co's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Shanghai Junshi Biosciences Co's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Shanghai Junshi Biosciences Co. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Shanghai Junshi Biosciences Co's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Shanghai Junshi Biosciences Co Margin History
| Shanghai Junshi Biosciences Co Gross margin | Shanghai Junshi Biosciences Co Profit margin | Shanghai Junshi Biosciences Co EBIT margin | Shanghai Junshi Biosciences Co Profit margin |
|---|---|---|---|
| 2029e | 57.78 % | 0 % | 0 % |
| 2028e | 57.78 % | 23.65 % | 0 % |
| 2027e | 57.78 % | 17.85 % | 0 % |
| 2026e | 57.78 % | -26.68 % | -7.07 % |
| 2025e | 57.78 % | -41.44 % | -24.41 % |
| 2024e | 57.78 % | -68.22 % | -80.23 % |
| 2023 | 57.78 % | -165.01 % | -151.97 % |
| 2022 | 63.79 % | -187.06 % | -164.3 % |
| 2021 | 68.74 % | -14.76 % | -17.91 % |
| 2020 | 76.37 % | -105.19 % | -104.62 % |
| 2019 | 88.3 % | -99.88 % | -96.43 % |
| 2018 | 34.48 % | -23,727.59 % | -24,927.59 % |
| 2017 | 90.46 % | -548.07 % | -582.2 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2017 | 90.46 % | -548.07 % | -582.2 % |
| 2018 | 34.48 % | -23,727.59 % | -24,927.59 % |
| 2019 | 88.3 % | -99.88 % | -96.43 % |
| 2020 | 76.37 % | -105.19 % | -104.62 % |
| 2021 | 68.74 % | -14.76 % | -17.91 % |
| 2022 | 63.79 % | -187.06 % | -164.3 % |
| 2023 | 57.78 % | -165.01 % | -151.97 % |
| 2024e | 57.78 % | -68.22 % | -80.23 % |
| 2025e | 57.78 % | -41.44 % | -24.41 % |
| 2026e | 57.78 % | -26.68 % | -7.07 % |
| 2027e | 57.78 % | 17.85 % | 0 % |
| 2028e | 57.78 % | 23.65 % | 0 % |
| 2029e | 57.78 % | 0 % | 0 % |
Shanghai Junshi Biosciences Co Aktienanalyse
What does Shanghai Junshi Biosciences Co do?
Shanghai Junshi Biosciences Co Ltd is a Chinese company specializing in biopharmaceutical research and development. It was founded in 2012 and is headquartered in Shanghai. The company's business model focuses on the development and manufacturing of innovative biopharmaceutical products. Its goal is to develop therapies for diseases that currently have no satisfactory treatment options. The company utilizes its experience in immuno-oncology and other areas of biopharmaceutical research. It has established different divisions for drug research and development, including immunoncology, inflammation, and infectious diseases. The company has a strong pipeline for developing new oncology drugs. It specializes in the development of monoclonal antibodies that are tailored to specific target processes and can provide customized treatment options for patients. The company's flagship products include Toripalimab, Tuoyi, and several preparations for the treatment of cancers such as lung, breast, stomach, liver, colorectal, and head and neck cancers. Toripalimab is a human monoclonal antibody used to treat advanced, recurrent, or metastatic melanoma. Tuoyi is an antibody that targets the human TNF-alpha protein, which is produced by white blood cells and promotes inflammation in the body. It is approved for the treatment of various rheumatic diseases such as rheumatoid arthritis. The company has also recently launched an RNA vaccine program to combat the COVID-19 virus and has shown its potential. Junshi has tested the first antiviral antibody for COVID-19 in humans. Overall, Shanghai Junshi Biosciences Co Ltd has quickly built a strong portfolio of business activities and established itself as a key player in the Chinese pharmaceutical market. The company is expected to continue playing a leading role in biopharmaceutical research and development in the future. Shanghai Junshi Biosciences Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.EBIT Details
Analyzing Shanghai Junshi Biosciences Co's EBIT
Shanghai Junshi Biosciences Co's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.
Year-to-Year Comparison
A yearly comparison of Shanghai Junshi Biosciences Co's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.
Impact on Investments
Shanghai Junshi Biosciences Co's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.
Interpreting EBIT Fluctuations
Fluctuations in Shanghai Junshi Biosciences Co’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.
Frequently Asked Questions about Shanghai Junshi Biosciences Co stock
What is EBIT?
EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Shanghai Junshi Biosciences Co.
How has the EBIT of Shanghai Junshi Biosciences Co developed in recent years?
The EBIT of Shanghai Junshi Biosciences Co has increased by -7.279% decreased compared to the previous year.
What does EBIT mean for investors?
EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.
Why is EBIT an important indicator for investors?
Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.
Why do EBIT values fluctuate?
EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.
What role does tax burden play in EBIT?
Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.
How is EBIT presented in the balance sheet of the company Shanghai Junshi Biosciences Co?
The EBIT of Shanghai Junshi Biosciences Co is listed in the income statement.
Can EBIT be used as a single indicator for evaluating a company?
EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.
Why is EBIT not equal to net profit?
The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.
How much dividend does Shanghai Junshi Biosciences Co pay?
Over the past 12 months, Shanghai Junshi Biosciences Co paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Shanghai Junshi Biosciences Co is expected to pay a dividend of 0 CNY.
What is the dividend yield of Shanghai Junshi Biosciences Co?
The current dividend yield of Shanghai Junshi Biosciences Co is .
When does Shanghai Junshi Biosciences Co pay dividends?
Shanghai Junshi Biosciences Co pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Shanghai Junshi Biosciences Co?
Shanghai Junshi Biosciences Co paid dividends every year for the past 0 years.
What is the dividend of Shanghai Junshi Biosciences Co?
For the upcoming 12 months, dividends amounting to 0 CNY are expected. This corresponds to a dividend yield of 0 %.
In which sector is Shanghai Junshi Biosciences Co located?
Shanghai Junshi Biosciences Co is assigned to the 'Health' sector.
Wann musste ich die Aktien von Shanghai Junshi Biosciences Co kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Shanghai Junshi Biosciences Co from 1/19/2025 amounting to 0 CNY, you needed to have the stock in your portfolio before the ex-date on 1/19/2025.
When did Shanghai Junshi Biosciences Co pay the last dividend?
The last dividend was paid out on 1/19/2025.
What was the dividend of Shanghai Junshi Biosciences Co in the year 2024?
In the year 2024, Shanghai Junshi Biosciences Co distributed 0 CNY as dividends.
In which currency does Shanghai Junshi Biosciences Co pay out the dividend?
The dividends of Shanghai Junshi Biosciences Co are distributed in CNY.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Shanghai Junshi Biosciences Co
Our stock analysis for Shanghai Junshi Biosciences Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Shanghai Junshi Biosciences Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
- Shanghai Junshi Biosciences Co Revenue
- Shanghai Junshi Biosciences Co Net Income
- Shanghai Junshi Biosciences Co P/E
- Shanghai Junshi Biosciences Co P/S
- Shanghai Junshi Biosciences Co EBIT
- Shanghai Junshi Biosciences Co Dividend
- Shanghai Junshi Biosciences Co Stocks
- Shanghai Junshi Biosciences Co Market capitalization
- Shanghai Junshi Biosciences Co Debt
- Shanghai Junshi Biosciences Co Liabilities
- Shanghai Junshi Biosciences Co Equity
- Shanghai Junshi Biosciences Co AAQS
- Shanghai Junshi Biosciences Co Employees
- Shanghai Junshi Biosciences Co ROE
- Shanghai Junshi Biosciences Co ROA
- Shanghai Junshi Biosciences Co ROCE
